FinTechFunding

Starpharma: Updates market on nasal spray

  • Starpharma has provided updates on its COVID-19 nasal protection spray, which uses antiviral dendrimer SPL7013
  • Already the company has identified a manufacturer and device components, undertook pilot manufacturing, and compiled regulatory documents
  • Depending on discussions with regulators, Starpharma expects to accelerate approval of a SPL7013 nasal spray
  • SPL7013 works by blocking the interaction between viral surface proteins and human cell receptor proteins
  • Further, Starpharma hasn’t ruled out other applications for SPL7013, such as injection, ocular (through the eye), or mist inhalation
  • Starpharma is currently up a steady 9.52 per cent and shares are trading for $1.15 each
Previous article
Metalicity: Confirms further high-grade gold at Liepold
Next article
Scentre Group: Posts $3.66B loss in 1HFY20
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Business Banking Fintech Slash Reaches Unicorn Status

The fintech startup achieves a valuation of over $1 billion.Highlights: Slash has been valued at over $1 billion.The...
FinTech

Amex Strengthens Digital Services with AI Expense Management Acquisition

American Express to acquire Hyper to enhance its business offerings.Highlights: American Express announces the acquisition of AI startup...
FinTech

UK Banks Strengthen Cybersecurity with Anthropics Mythos Model

New collaboration enhances banks' defense against cyber threats.Highlights: UK banks to access Anthropics Mythos model in the upcoming...
FinTech

UK Banks to Gain Access to Anthropic Cybersecurity Model Next Week

New collaboration enhances cybersecurity for UK banking institutions.Highlights: UK banks set to access Anthropic's cybersecurity model soon.Collaboration aims...